)
Arcutis Biotherapeutics (ARQT) investor relations material
Arcutis Biotherapeutics TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Financial performance and growth
Achieved $127.5 million in Q4 net revenue, exceeding consensus by $15 million, and $372 million for the year, with TRX doubling year-over-year.
Portfolio-wide growth in Q4, with 19% demand growth and gross-to-net maintained in the 50s; expecting typical seasonality in Q1 2026.
Cash flow breakeven reached last quarter, with commitment to maintain positive cash flow and operating leverage as top-line grows faster than expenses.
Profitable in Q3 and Q4, with profits expected to fluctuate due to non-cash items, but cash management remains a priority.
Commercial strategy and market expansion
Holds nearly 50% of the branded nonsteroidal topical market, with strong execution and additional product approvals in 2025.
Dermatology sales force expanding by 30 representatives to 160, targeting mid-decile prescribers for broader reach.
Building a dedicated primary care and pediatric sales force, starting with a pilot of 30, aiming for impact in the back half of the year.
Partnership with PGA golfer Max Homa to raise awareness for seborrheic dermatitis and ZORYVE.
Medicare formulary win gives access to one-third of Medicare lives, with plans to expand further in 2026-2027.
Product pipeline and R&D updates
NDA filing for ZORYVE in infants (3-24 months) planned for Q2, with anticipated approval for plaque psoriasis in ages 2-5 by end of June.
Ongoing Phase II trials in hidradenitis suppurativa (HS) and vitiligo, with promising early case reports; POC studies to guide further development.
ARQ-234, a novel atopic dermatitis treatment, entering the clinic this quarter, targeting immune checkpoint agonism for potential disease remission.
Additional POC studies in other indications planned for 2024, with prioritization based on clinical promise.
Next Arcutis Biotherapeutics earnings date
Next Arcutis Biotherapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)